US Patent

US11529431 — Methods for making ultrasound contrast agents

Method of Use · Assigned to Lantheus Medical Imaging Inc · Expires 2037-03-16 · 11y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects improved methods for preparing phospholipid formulations, including those used as ultrasound contrast agents.

USPTO Abstract

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Drugs covered by this patent

perflutren (PERFLUTREN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-665`	—	perflutren
`U-665`	—	perflutren

Patent Metadata

Patent number: US11529431
Jurisdiction: US
Classification: Method of Use
Expires: 2037-03-16
Drug substance claim: No
Drug product claim: No
Assignee: Lantheus Medical Imaging Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.